Clinical Trial Update: Ecteinascidin 743 in Treating Patients With Malignant Mesothelioma [Phase 2]

View source ↗

Summary

PharmaMar reports the termination of a Phase 2 trial of Ecteinascidin 743 (trabectedin) in malignant mesothelioma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Mesothelioma

Drugs mentioned

• Yondelis (trabectedin)

Snippet

Sponsor: PharmaMar | Conditions: Malignant Mesothelioma | Phase 2 | Status: TERMINATED